80 seems overvalued for VKTX
80 is enuf!!! $Viking Therapeutics, Inc.(VKTX)$
While VKTX-2735 has shown promising safety profiles in early studies, ramping up the dosage could potentially introduce unforeseen risks. Investors might fret over increased adverse reactions with higher doses, casting doubt on its commercial viability and market acceptance
tho its potential for significant weight loss, VKTX-2735 faces an uphill battle in a fiercely competitive weight loss drug market. established players like Semaglutide and Tirzepatide already dominate, raising questions about VKTX-2735's ability to carve out a significant market share and achieve commercial success
and VKTX-2735 is still in the clinical trial phase, and its path to market approval depends on regulatory bodies like the FDA. Any delays or setbacks in the regulatory approval process could spell trouble for the stock price
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
